Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) Director Ken Takanashi acquired 22,053,581 shares of Satsuma Pharmaceuticals stock in a transaction dated Tuesday, June 6th. The shares were purchased at an average price of $0.91 per share, with a total value of $20,068,758.71. Following the acquisition, the director now owns 24,847,694 shares of the company’s stock, […]
Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) was the recipient of a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 130,100 shares, a decrease of 58.0% from the April 30th total of 310,100 shares. Approximately 0.5% of the shares of the stock are sold […]
NEA Management Company LLC lessened its position in Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) by 4.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,992,958 shares of the financial services provider’s stock after selling 150,000 shares during the […]
Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) saw a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 159,400 shares, a decrease of 40.4% from the March 15th total of 267,500 shares. Based on an average daily trading volume, of 152,700 shares, the short-interest ratio […]
Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) was the recipient of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 159,400 shares, a decrease of 40.4% from the March 15th total of 267,500 shares. Based on an average trading volume of 152,700 shares, the […]